Improved HIV Genotypic Resistance Assay

An improved HIV genotypic resistance assay is designed to be a more sensitive assay at low viral load levels. It will also aid both doctors and patients by shortening the turnaround time for results and providing a more user-friendly report.

The new assay, called HIV GenoSure, was developed by Laboratory Corp. of America (Burlington, NC, USA), using the company's database of over 40,000 genotypic and phenotypic specimens. The company created a mutational cluster analysis (MCA) software program to interpret genotypic results as either "sensitive,” "resistance possible,” or "resistant.” LabCorp also offers the HIV GenoSure Plus Assay, a genotyping test plus a predictive phenotype result using a correlation database.

"As one of the largest providers of HIV testing services in the United States, we are committed to advancing the state of the art in genotypic resistance testing,” said Myla P. Lai-Goldman, M.D., executive vice president and medical director at LabCorp.



Related Links:
LabCorp